Radspherin is under clinical development by Oncoinvent and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Radspherin’s likelihood of approval (LoA) and phase transition for Peritoneal Cancer took place on 19 Sep 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Radspherin Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Radspherin overview

Radspherin, is under development for the treatment of metastatic cancers including peritoneal carcinomatosis originating from ovarian cancer, fallopian cancer, peritoneal cancer and colorectal cancer. It constitutes a monoclonal antibody OI-3 conjugated to a radioisotope or toxin. The drug candidate is a suspension of inorganic alpha-emitting radioactive microspheres and administered as intraperitoneal injection. It acts by targeting CD146 antigen.

Oncoinvent overview

Oncoinvent is a monoclonal antibodies product manufacturer. The company develops and manufactures therapeutic product for the treatment of various cancer. It develops Radspherin technology, an alpha-emitting radioactive microsphere, which is designed for treatment of metastatic cancers in body cavities. Oncoinvent’s Radspherin technology is an anticipated that the product can potentially treat several forms of metastatic cancer, ovarian cancer and colorectal cancer. It platforms through injections, medicines and liquids. The company carters its products under the brand Radspherin. Oncoinvent is headquartered in Oslo city, Oslo, Norway.

Quick View Radspherin LOA Data

Report Segments
  • Innovator
Drug Name
  • Radspherin
Administration Pathway
  • Intraperitoneal
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.